More on CRVS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $13.93 |
|
|||
| Open | $13.76 | ||||
| 52 Wk High | $17.77 | ||||
| 52 Wk Low | $9.63 | ||||
| Day High | $13.91 | ||||
| Day Low | $12.95 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,106,824 | ||||
- Corvus Pharmaceuticals publishes soquelitinib Phase 1 T cell data in Blood
- Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
- Form SCHEDULE 13G Corvus Pharmaceuticals, Filed by: STATE STREET CORP
- Corvus Pharmaceuticals, Inc. (CRVS) Misses Q2 EPS by 4c
- Form 10-Q Corvus Pharmaceuticals, For: Jun 30
- Form 8-K Corvus Pharmaceuticals, For: Aug 06
- Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
- Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
- Ladenburg Thalmann Assumes Corvus Pharmaceuticals (CRVS) at Buy
- Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: BlackRock, Inc.
Entities mentioned with CRVS
- FDA | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- 13G | View Related Stories »
- Jefferies & Co | View Related Stories »
- OrbiMed Advisors | View Related Stories »
- Show More...
